Pediatric Drugs

, Volume 15, Issue 2, pp 71–81

Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date

  • Shahrad Rod Rassekh
  • Colin J. D. Ross
  • Bruce C. Carleton
  • Michael R. Hayden
Leading Article

Abstract

Over the last few decades, cure rates for pediatric cancer have increased dramatically, and now over 80 % of children with cancer are cured of their disease. This improvement in cure has come with a significant cost, with many children suffering irreversible, life-threatening, or long-lasting toxicities due to the medications required during their treatment. In the last 2 decades, major technological advances in genomics and the mapping of the human genome have made it possible to identify genetic differences between children in order to investigate differing responses to cancer therapy and to help explain why children treated with the same medications can have different outcomes. The emerging field of pharmacogenomics has had many important findings in pediatric cancer. The focus of this review is drug toxicity in pediatric cancer and the use of pharmacogenomics to reduce these adverse drug reactions, with a specific focus on thiopurines, methotrexate, cisplatin, vincristine and anthracyclines. Future areas of research and the need for international collaboration are discussed.

References

  1. 1.
    Ellison LF, De P, Mery LS, et al. Canadian cancer statistics at a glance: cancer in children. CMAJ. 2009;180(4):422–4.PubMedGoogle Scholar
  2. 2.
    Mitchell AA, Lacouture PG, Sheehan JE, et al. Adverse drug reactions in children leading to hospital admission. Pediatrics. 1988;82(1):24–9.PubMedGoogle Scholar
  3. 3.
    Geenen MM, Cardous-Ubbink MC, Kremer LCM, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705–15.PubMedGoogle Scholar
  4. 4.
    Impicciatore M. Pharmacogenomic can give children safer medicines. Arch Dis Child. 2003;88(4):366.PubMedGoogle Scholar
  5. 5.
    Jaja C, Rothstein M. Pharmacogenomics. New York: Wiley; 2003.Google Scholar
  6. 6.
    Kling J. US FDA contemplates collection of pharmacogenomic data. Nat Biotechnol. 2003;21(6):590.PubMedGoogle Scholar
  7. 7.
    Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301–6.PubMedGoogle Scholar
  8. 8.
    Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–9.PubMedGoogle Scholar
  9. 9.
    Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–87.PubMedGoogle Scholar
  10. 10.
    Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr Opin Pediatr. 2007;19(1):15–22.PubMedGoogle Scholar
  11. 11.
    Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51.PubMedGoogle Scholar
  12. 12.
    Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.PubMedGoogle Scholar
  13. 13.
    Paugh SW, Stocco G, Evans WE. Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr. 2010;22(6):703–10.PubMedGoogle Scholar
  14. 14.
    Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene. 2006;25(11):1629–38.PubMedGoogle Scholar
  15. 15.
    Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6(2):117–29.PubMedGoogle Scholar
  16. 16.
    Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14(7):407–17.PubMedGoogle Scholar
  17. 17.
    Schaeffeler E, Lang T, Zanger UM, et al. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem. 2001;47(3):548–55.PubMedGoogle Scholar
  18. 18.
    Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Int Med. 1997;126(8):608–14.PubMedGoogle Scholar
  19. 19.
    Coulthard SA, Howell C, Robson J, et al. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood. 1998;92(8):2856–62.PubMedGoogle Scholar
  20. 20.
    Pui CH, Evans WE. Drug therapy: treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–78.PubMedGoogle Scholar
  21. 21.
    Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6(4):279–90.PubMedGoogle Scholar
  22. 22.
    Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999;16(3):342–9.PubMedGoogle Scholar
  23. 23.
    McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltransferase activity in American White subjects and lack subjects. Clin Pharmacol Ther. 1994;55(1):15–20.PubMedGoogle Scholar
  24. 24.
    McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart-transplant recipient. Lancet. 1993;341(8853):1151.PubMedGoogle Scholar
  25. 25.
    Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effect, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic-leukemia. J Pediatr. 1991;119(6):985–9.PubMedGoogle Scholar
  26. 26.
    Schutz E, Gummert J, Mohr F, et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart-transplant recipient. Lancet. 1993;341(8842):436.PubMedGoogle Scholar
  27. 27.
    Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85(2):164–72.PubMedGoogle Scholar
  28. 28.
    Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293(12):1485–9.PubMedGoogle Scholar
  29. 29.
    Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998;12(3):346–52.PubMedGoogle Scholar
  30. 30.
    Thomsen JB, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer. 1999;86(6):1080–6.Google Scholar
  31. 31.
    Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354(9172):34–9.PubMedGoogle Scholar
  32. 32.
    Stanulla M, Schaeffeler E, Moricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin–Frankfurt–Munster protocols. Blood. 2009;114(7):1314–8.PubMedGoogle Scholar
  33. 33.
    Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood. 2009;113(24):6077–84.PubMedGoogle Scholar
  34. 34.
    Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics. 2006;16(12):847–54.PubMedGoogle Scholar
  35. 35.
    Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387–91.PubMedGoogle Scholar
  36. 36.
    Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte. An update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.PubMedGoogle Scholar
  37. 37.
    Relling MV, Pui CH, Cheng C, et al. Thiopurine methyltransferease in acute lymphoblastic leukemia. Blood. 2006;107(2):843–4.PubMedGoogle Scholar
  38. 38.
    Veenstra DL, Higashi MK. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2(3):E29.PubMedGoogle Scholar
  39. 39.
    Donnan JR, Ungar WJ, Mathews M, et al. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(2):231–9.PubMedGoogle Scholar
  40. 40.
    Cheng KKF. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer. Eur J Cancer Care. 2008;17(3):306–11.Google Scholar
  41. 41.
    Jolivet J, Schilsky RL, Bailey BD, et al. Synthesis, retention, and biological-activity of methotrexate polyglutamates in cultured human-breast cancer-cells. J Clin Invest. 1982;70(2):351–60.PubMedGoogle Scholar
  42. 42.
    Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate: is methotrexate a prodrug. J Clin Invest. 1985;76(3):907–12.PubMedGoogle Scholar
  43. 43.
    Zhao RB, Goldman ID. Resistance to antifolates. Oncogene. 2003;22(47):7431–57.PubMedGoogle Scholar
  44. 44.
    Fabre I, Fabre G, Goldman ID. Polyglutamation, an important element in methotrexate cytotoxicity nd selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res. 1984;44(8):3190–5.PubMedGoogle Scholar
  45. 45.
    Shimasaki N, Mori T, Samejinia R, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006;28(2):64–8.PubMedGoogle Scholar
  46. 46.
    Robaey P, Krajinovic M, Marcoux S, et al. Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy. Dev Disabil Res Rev. 2008;14(3):211–20.PubMedGoogle Scholar
  47. 47.
    Jaksic W, Veljkovic D, Pozza C, et al. Methotrexate-induced leukoencephalopathy reversed by aminophylline and high-dose folinic acid. Acta Haematologica. 2004;111(4):230–2.PubMedGoogle Scholar
  48. 48.
    Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9.PubMedGoogle Scholar
  49. 49.
    Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G(80)A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100(10):3832–4.PubMedGoogle Scholar
  50. 50.
    Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004;14(11):733–9.PubMedGoogle Scholar
  51. 51.
    Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21(16):3084–91.PubMedGoogle Scholar
  52. 52.
    Ziereisen F, Dan B, Azzi N, et al. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol. 2006;36(3):205–12.PubMedGoogle Scholar
  53. 53.
    Reddick WE, Glass JO, Helton KJ, et al. A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. Am J Neuroradiol. 2005;26(9):2371–7.PubMedGoogle Scholar
  54. 54.
    Reddick WE, Glass JO, Helton KJ, et al. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. Am J Neuroradiol. 2005;26(5):1263–9.PubMedGoogle Scholar
  55. 55.
    Linnebank M, Moskau S, Jurgens A, et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol. 2009;11(1):2–8.PubMedGoogle Scholar
  56. 56.
    Muller J, Kralovanszky J, Adleff V, et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res. 2008;28(5B):3051–4.PubMedGoogle Scholar
  57. 57.
    Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98(1):231–4.PubMedGoogle Scholar
  58. 58.
    Krull KR, Brouwers P, Jain N, et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr. 2008;152(1):101–5.PubMedGoogle Scholar
  59. 59.
    Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005;65(6):2482–7.PubMedGoogle Scholar
  60. 60.
    Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91(8):1113–6.PubMedGoogle Scholar
  61. 61.
    Ruiz-Argueles GJ, Coconi-Linares LN, Garces-Eisele J, et al. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology. 2007;12(5):387–91.Google Scholar
  62. 62.
    Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004;4(1):66–72.PubMedGoogle Scholar
  63. 63.
    Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62(11):3144–50.PubMedGoogle Scholar
  64. 64.
    Zeng H, Chen ZS, Belinsky MG, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001;61(19):7225–32.PubMedGoogle Scholar
  65. 65.
    Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma. Cancer. 2012;118(7):1856–67.PubMedGoogle Scholar
  66. 66.
    Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(4):612–9.PubMedGoogle Scholar
  67. 67.
    Treviño LR, Shimasaki N, Yang WJ, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–8.PubMedGoogle Scholar
  68. 68.
    Brock P, Bellman S. Ototoxicity of cisplatinum. Br J Cancer. 1991;63(1):159–60.PubMedGoogle Scholar
  69. 69.
    McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8(1):10–6.PubMedGoogle Scholar
  70. 70.
    Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–24.PubMedGoogle Scholar
  71. 71.
    Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77(8):1355–62.PubMedGoogle Scholar
  72. 72.
    Brock PR, Yeomans EC, Bellman SC, et al. Cisplatin therapy in infants-short and long-term morbidity. Br J Cancer. 1992;66:S36–40.Google Scholar
  73. 73.
    Coradini PP, Cigana L, Selistre SGA, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355–60.PubMedGoogle Scholar
  74. 74.
    Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588–96.PubMedGoogle Scholar
  75. 75.
    Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40(16):2445–51.PubMedGoogle Scholar
  76. 76.
    Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107(2):417–22.PubMedGoogle Scholar
  77. 77.
    Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998;19(5):339–54.PubMedGoogle Scholar
  78. 78.
    Dionne F, Mitton C, Rassekh R, et al. Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics J. 2012;12(3):205–13.PubMedGoogle Scholar
  79. 79.
    Shord SS, Thompson DM, Krempl GA, et al. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs. 2006;17(2):207–15.PubMedGoogle Scholar
  80. 80.
    Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11(8):639–43.PubMedGoogle Scholar
  81. 81.
    Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25(6):708–14.PubMedGoogle Scholar
  82. 82.
    Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 2008;8(1):23–8.PubMedGoogle Scholar
  83. 83.
    Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009;9(5):347–53.PubMedGoogle Scholar
  84. 84.
    Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–5.PubMedGoogle Scholar
  85. 85.
    Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10(15):4939–43.PubMedGoogle Scholar
  86. 86.
    Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11(4):1534–8.PubMedGoogle Scholar
  87. 87.
    Carleton BC, Poole RL, Smith MA, et al. Adverse drug reaction active surveillance: developing a national network in Canada’s children’s hospitals. Pharmacoepidemiol Drug Saf. 2009;18(8):713–21.PubMedGoogle Scholar
  88. 88.
    Ross C, Katzov-Eckert H, Dube M, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41(12):1345–9.PubMedGoogle Scholar
  89. 89.
    Chauvenet AR, Shashi V, Selsky C, et al. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003;25:316–20.PubMedGoogle Scholar
  90. 90.
    Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–7.PubMedGoogle Scholar
  91. 91.
    Gidding CEM, Meeuwsen-de Boer GJ, Koopmans P, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol. 1999;44(3):203–9.PubMedGoogle Scholar
  92. 92.
    Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. Bethesda: American Society of Health-System Pharmacists; 2005.Google Scholar
  93. 93.
    Tarlaci S. Vincristine-induced fatal neuropathy in non-Hodgkin’s lymphoma. Neurotoxicology. 2008;29(4):748–9.PubMedGoogle Scholar
  94. 94.
    Toghill PJ, Burke JD. Death from paralytic ileus following vincristine therapy. Postgrad Med J. 1970;46(535):330–1.PubMedGoogle Scholar
  95. 95.
    Kuruvilla G, Perry S, Wilson B, et al. The natural history of vincristine-induced laryngeal paralysis in children. Arch Otolaryngol Head Neck Surg. 2009;135(1):101–5.PubMedGoogle Scholar
  96. 96.
    Callizot N, Andriambeloson E, Glass J, et al. Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity. Cancer Chemother Pharmacol. 2008;62(6):995–1007.PubMedGoogle Scholar
  97. 97.
    Verstappen CCP, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64(6):1076–7.PubMedGoogle Scholar
  98. 98.
    Dougherty PM, Cata JP, Burton AW, et al. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage. 2007;33(2):166–79.PubMedGoogle Scholar
  99. 99.
    Crom WR, Degraaf SSN, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125(4):642–9.PubMedGoogle Scholar
  100. 100.
    Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008;50(4):769–71.PubMedGoogle Scholar
  101. 101.
    Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34(8):1317–27.PubMedGoogle Scholar
  102. 102.
    Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007;321(2):553–63.PubMedGoogle Scholar
  103. 103.
    Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos. 2000;28(9):1121–7.PubMedGoogle Scholar
  104. 104.
    Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383–91.PubMedGoogle Scholar
  105. 105.
    Xie HG, Wood AJJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5(3):243–72.PubMedGoogle Scholar
  106. 106.
    van Dalen EC, van der Pal HJH, Kok WEM, et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42(18):3191–8.PubMedGoogle Scholar
  107. 107.
    Kremer LCM, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13(4):503–12.PubMedGoogle Scholar
  108. 108.
    Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808–15.PubMedGoogle Scholar
  109. 109.
    Vonhoff DD, Layard MW, Basa P, et al. Risk-factors for doxorubicin-induced congestive heart-failure. Ann Int Med. 1979;91(5):710–7.Google Scholar
  110. 110.
    Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.PubMedGoogle Scholar
  111. 111.
    Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the childhood cancer survivor study. J Clin Oncol. 2001;19(13):3163–72.PubMedGoogle Scholar
  112. 112.
    Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172–9.PubMedGoogle Scholar
  113. 113.
    Kremer LCM, van der Pal HJH, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13(6):819–29.PubMedGoogle Scholar
  114. 114.
    Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011;32(3):342–53.PubMedGoogle Scholar
  115. 115.
    Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–33.PubMedGoogle Scholar
  116. 116.
    Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754–62.PubMedGoogle Scholar
  117. 117.
    Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia. 2009;23(6):1118–26.PubMedGoogle Scholar
  118. 118.
    Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H : quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112(12):2789–95.PubMedGoogle Scholar
  119. 119.
    Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009;50(10):1693–8.PubMedGoogle Scholar
  120. 120.
    Semsei AF, Erdelyi DJ, Ungvari I, et al. ABCC1 polymorphisms in anthracycline cardiotoxicity in childhood acute lymphoblastic leukemia. Cell Biol Int. 2012;36:79–86.PubMedGoogle Scholar
  121. 121.
    Visscher H, Ross CJD, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422–8.PubMedGoogle Scholar
  122. 122.
    Ross CJD, Visscher H, Sistonen J, et al. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid. 2010;20(7):681–7.PubMedGoogle Scholar
  123. 123.
    Carleton B. Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations. Clin Pharmacol Ther. 2010;88(6):757–9.PubMedGoogle Scholar
  124. 124.
    Hudson MM, Ness KK, Nolan VG, et al. Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2011;56(5):825–36.PubMedGoogle Scholar
  125. 125.
    Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Ann Rev Med. 2006;57:119–37.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Shahrad Rod Rassekh
    • 1
    • 2
    • 6
  • Colin J. D. Ross
    • 2
    • 3
    • 4
  • Bruce C. Carleton
    • 2
    • 3
  • Michael R. Hayden
    • 4
    • 5
  1. 1.Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMTUniversity of British ColumbiaVancouverCanada
  2. 2.Child and Family Research InstituteBritish Columbia’s Children’s HospitalVancouverCanada
  3. 3.Department of Pediatrics, Division of Translational TherapeuticsUniversity of British ColumbiaVancouverCanada
  4. 4.Department of Medical GeneticsUniversity of British ColumbiaVancouverCanada
  5. 5.Centre for Molecular Medicine and TherapeuticsUniversity of British ColumbiaVancouverCanada
  6. 6.Division of Pediatric Hematology/Oncology/BMTBC Children’s HospitalVancouverCanada

Personalised recommendations